67629-33-8 Usage
Uses
Used in Pharmaceutical Industry:
[1,2,4]Triazolo[4,3-a]quinazoline-1,5-dione, 2,4-dihydro-4-phenylis used as a potential therapeutic agent for its anticancer properties. [1,2,4]Triazolo[4,3-a]quinazoline-1,5-dione, 2,4-dihydro-4-phenylhas shown promise in targeting and inhibiting the growth of cancer cells, making it a valuable candidate for the development of new cancer treatments.
Used in Antiviral Applications:
In the field of antiviral research, [1,2,4]Triazolo[4,3-a]quinazoline-1,5-dione, 2,4-dihydro-4-phenylis used as a potential antiviral agent. Its ability to interfere with viral replication and inhibit the spread of viruses makes it a candidate for the development of new antiviral medications.
Used in Drug Development:
[1,2,4]Triazolo[4,3-a]quinazoline-1,5-dione, 2,4-dihydro-4-phenylis used as a key compound in the development of new drugs. Its unique structure and pharmacological properties make it an attractive starting point for the design and synthesis of novel therapeutic agents targeting various diseases, including cancer and viral infections.
Used in Research and Development:
In the scientific community, [1,2,4]Triazolo[4,3-a]quinazoline-1,5-dione, 2,4-dihydro-4-phenylis used as a subject of study for understanding its synthesis, structure-activity relationships, and pharmacological potential. This research contributes to the advancement of medical knowledge and the development of new therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 67629-33-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,6,2 and 9 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 67629-33:
(7*6)+(6*7)+(5*6)+(4*2)+(3*9)+(2*3)+(1*3)=158
158 % 10 = 8
So 67629-33-8 is a valid CAS Registry Number.
67629-33-8Relevant academic research and scientific papers
Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one and Its Derivatives
Zhang, Hong-Jian,Jin, Peng,Wang, Shi-Ben,Li, Fu-Nan,Guan, Li-Ping,Quan, Zhe-Shan
, p. 564 - 574 (2015/08/06)
A series of 4-(substituted-phenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones (6a-x) with triazole and other heterocyclic substituents (7-14) were synthesized and the compounds were evaluated for their anticonvulsant activity and neurotoxicity by maximal electroshock (MES) and rotarod neurotoxicity tests. Among the compounds studied, 6o and 6q showed wide margins of safety with protective indices (PIs) that were much higher than those of currently used drugs (PI6o > 25.5, PI6q > 26.0). Compounds 6o and 6q showed significant oral activity against MES-induced seizures in mice, with ED50 values of 88.02 and 94.6 mg/kg, respectively. The two compounds were also found to have potent activity against seizures that were induced by pentylenetetrazole and bicuculline. A series of 4-(substituted-phenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones with triazole and other heterocyclic substituents were synthesized and the compounds were evaluated for their anticonvulsant activity and neurotoxicity using maximal electroshock and rotarod neurotoxicity tests.
